| In millions, except per share items | Jun-30-19 | Jun-30-18 | Jun-30-17 | Jun-30-16 | Jun-30-15 | Jun-30-14 | Jun-30-13 | Jun-30-12 |
| | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Laboratory testing services | 12.2 | 15.3 | 18.9 | | 24.4 | | | |
| Web-based software | 0.8 | 1.0 | 1.3 | | | | | |
| Total revenues [+] | 12.9 | 16.3 | 20.2 | 34.6 | 24.4 | 5.6 | 4.8 | 3.2 |
| Services | | | | 34.0 | 24.4 | | | |
| Technology services | | | | 0.6 | | 2.2 | 2.7 | 2.6 |
| Healthcare | | | | 0.0 | | 3.3 | 2.1 | 0.6 |
| Revenue growth [+] | -20.7% | -19.3% | -41.6% | 41.4% | 340.0% | 15.1% | 51.4% | 8.6% |
| Laboratory testing services | -20.5% | -19.1% | | | | | | |
| Web-based software | -23.1% | -22.9% | | | | | | |
| Cost of goods sold | 5.0 | 5.1 | 4.2 | 6.9 | 4.2 | 3.8 | 3.5 | 2.6 |
| Gross profit | 7.9 | 11.2 | 16.0 | 27.7 | 20.2 | 1.8 | 1.4 | 0.6 |
| Gross margin | 61.3% | 68.5% | 79.2% | 80.1% | 82.7% | 32.3% | 28.4% | 18.8% |
| Selling, general and administrative | 10.0 | 10.4 | 14.3 | 19.2 | 9.0 | 7.0 | 6.8 | 6.4 |
| Research and development | | | | | | 1.1 | 1.1 | 0.9 |
| Equity in earnings | | | | | | | | |
| Other operating expenses | -0.2 | 0.8 | 0.3 | 1.6 | | | | |
| EBITDA [+] | -1.9 | 0.0 | 1.4 | 6.9 | 11.2 | -6.4 | -6.5 | -6.7 |
| EBITDA growth | -8753.6% | -98.5% | -79.5% | -38.2% | -277.1% | -2.7% | -2.4% | 12.3% |
| EBITDA margin | -14.7% | 0.1% | 7.0% | 20.1% | 46.0% | -114.3% | -135.2% | -209.8% |
| Depreciation | 0.5 | 0.8 | 1.7 | 1.1 | 0.9 | 0.4 | 0.6 | 0.8 |
| EBITA | -2.4 | -0.8 | -0.2 | 5.8 | 10.4 | -6.8 | -7.1 | -7.5 |
| EBITA margin | -18.3% | -4.8% | -1.2% | 16.8% | 42.5% | -122.1% | -146.7% | -235.8% |
| Amortization of intangibles | | | | | | 0.3 | 0.3 | 0.2 |
| EBIT [+] | -2.4 | -0.8 | -0.2 | 5.8 | 10.4 | -7.1 | -7.4 | -7.7 |
| EBIT growth | 203.7% | 219.1% | -104.2% | -44.2% | -246.0% | -3.4% | -4.4% | 7.8% |
| EBIT margin | -18.3% | -4.8% | -1.2% | 16.8% | 42.5% | -128.1% | -152.7% | -241.8% |
| Non-recurring items [+] | 0.6 | | 5.1 | | | | | |
| Asset impairment | | | 5.1 | | | | | |
| Interest expense, net [+] | 0.2 | 0.1 | 0.5 | 0.2 | 0.0 | | | 0.0 |
| Interest expense | 0.2 | 0.1 | 0.5 | 0.2 | | | | |
| Interest income | | | | | 0.0 | | | 0.0 |
| Other income (expense), net [+] | 0.5 | -1.0 | 0.4 | 0.0 | -1.1 | 0.0 | -4.0 | -0.6 |
| Unrealized gain/loss on derivatives | 0.6 | -0.8 | 0.8 | | | | | |
| Other non-ooperating expenses | -0.1 | -0.2 | -0.2 | | | | | |
| Other | -0.1 | -0.2 | -0.2 | | | 0.0 | -4.0 | -0.6 |
| Pre-tax income | -2.7 | -1.9 | -5.4 | 5.6 | 9.3 | -7.1 | -11.3 | -8.4 |
| Income taxes | 5.3 | -6.1 | 26.6 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 320.3% | | 5.8% | 0.2% | 0.0% | 0.0% | 0.0% |
| Net income | -8.3 | -8.3 | -32.4 | 5.1 | 9.2 | -7.1 | -11.3 | -8.4 |
| Net margin | -64.3% | -51.2% | -160.6% | 14.8% | 37.8% | -128.6% | -235.1% | -262.0% |
| |
| Basic EPS [+] | ($1.01) | ($1.15) | ($4.51) | $1.72 | $9.64 | ($0.19) | ($0.40) | ($0.32) |
| Growth | -11.8% | -74.5% | -363.0% | -82.2% | -5120.8% | -52.5% | 24.3% | 5.1% |
| Diluted EPS [+] | ($1.01) | ($1.15) | ($4.51) | $1.27 | $9.64 | ($0.19) | ($0.40) | ($0.32) |
| Growth | -11.8% | -74.5% | -455.0% | -86.8% | -5120.8% | -52.5% | 24.3% | 5.1% |
| |
| Dividends per share [+] | | | | | | $0.00 | $0.00 | $0.00 |
| Growth | | | | | -100.0% | -24.5% | -8.5% | -32.1% |
| |
| Shares outstanding (basic) [+] | 8.2 | 7.2 | 7.2 | 3.0 | 1.0 | 37.2 | 28.1 | 25.7 |
| Growth | 13.1% | 0.8% | 141.6% | 210.6% | -97.4% | 32.4% | 9.3% | 17.1% |
| Shares outstanding (diluted) [+] | 8.2 | 7.2 | 7.2 | 4.0 | 1.0 | 37.2 | 28.1 | 25.7 |
| Growth | 13.1% | 0.8% | 79.0% | 319.3% | -97.4% | 32.4% | 9.3% | 17.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |